# US Cardiac Biomarkers Market > US Cardiac Biomarkers Market Research Report: Size, Share, Trend Analysis By Types (Creatine Kinase (CK-MB), Troponins T, Imyoglobin, BNPs, IMA, Others), By Location of Testing (Point of Care, Laboratory Testing) and By Applications (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 12.02% - **2024:** $ 3,072 Million - **2025:** $ 3,441.25 Million - **2035:** $ 10,709.28 Million - **Key Players:** Roche Diagnostics (CH), Abbott Laboratories (US), Siemens Healthineers (DE), Ortho Clinical Diagnostics (US), Thermo Fisher Scientific (US), bioMérieux (FR), QuidelOrtho Corporation (US), Boehringer Ingelheim (DE), F. Hoffmann-La Roche AG (CH) **Report ID:** MRFR/HC/11296-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-cardiac-biomarkers-market-12821 --- ## Market Summary ## **US Cardiac Biomarkers Market Overview** As per MRFR analysis, the US Cardiac Biomarkers Market Size was estimated at 2.77 (USD Billion) in 2023. The US Cardiac Biomarkers Market Industry is expected to grow from 3.6(USD Billion) in 2024 to 12.5 (USD Billion) by 2035. The US Cardiac Biomarkers Market CAGR (growth rate) is expected to be around 11.981% during the forecast period (2025 - 2035). ### **Key US Cardiac Biomarkers Market Trends Highlighted** The US Cardiac Biomarkers Market is currently witnessing significant trends driven largely by the rising prevalence of cardiovascular diseases across the nation. As reported by the CDC, heart disease remains a leading cause of death in the United States, pushing healthcare providers and institutions to invest in innovative diagnostic tools, including cardiac biomarkers. This increasing focus on early diagnosis and preventive care is a crucial market driver, promoting the development and adoption of advanced biomarker tests that enhance patient outcomes. Opportunities in this market are plentiful, particularly as technology evolves. The integration of point-of-care testing and the use of digital health solutions are reshaping the landscape. There is a growing demand for rapid testing options that can provide results promptly in emergency settings, enhancing the ability to triage patients effectively. Manufacturers are also looking toward partnerships with technology companies to develop mobile applications and telehealth services that enable continuous monitoring of cardiac health, which can further improve patient management. In recent times, trends such as personalized medicine and the move towards precision diagnostics have gained traction in the US market. Healthcare providers are increasingly interested in tailoring treatment plans based on individual patient profiles and biomarker levels. Additionally, regulatory bodies like the FDA are promoting streamlined approval processes for innovative cardiac biomarker tests, which further stimulates market growth. With aging demographics and an emphasis on chronic disease management, the future of the US [Cardiac Biomarkers](../../../reports/cardiac-biomarkers-market-8594) Market looks promising as it continues to adapt to the evolving needs of healthcare providers and patients alike. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## **US Cardiac Biomarkers Market Drivers** ### **Rising Prevalence of Cardiovascular Diseases** The prevalence of cardiovascular diseases in the United States has been steadily increasing, largely attributed to factors such as obesity, sedentary lifestyles, and aging populations. According to the American Heart Association, approximately 697,000 individuals die from heart disease annually in the US, representing nearly 1 in every 5 deaths. This growing prevalence of cardiovascular conditions is a major driver for the US Cardiac Biomarkers Market Industry as healthcare providers continuously seek innovative diagnostic tools to improve patient outcomes. The introduction of advanced cardiac biomarkers aids in early detection and risk stratification, enhancing treatment effectiveness. Companies such as Abbott Laboratories and Roche have been at the forefront, focusing their Research and Development investments on the development of new biomarkers aimed at better diagnosis and management of heart diseases. The rising demand for such innovations is expected to significantly contribute to market growth in the coming years. ### **Technological Advancements in Diagnostic Tools** Advancements in diagnostic technologies have been a crucial factor in enhancing the accuracy and efficiency of cardiac biomarker tests. Innovations, including point-of-care testing platforms and high-sensitivity assays, have elevated the US Cardiac Biomarkers Market Industry significantly. The US Food and Drug Administration has recently approved several high-sensitivity troponin assays that allow for faster and more reliable heart attack diagnoses. Research conducted by the National Institutes of Health indicates that the introduction of these technologies can reduce the time to diagnosis by up to 50%. Hence, the integration of advanced technologies not only improves patient management but also drives the demand for new biomarker tests and products from established companies like Abbott and Siemens Healthineers, who invest heavily in this domain. ### **Increasing Focus on Personalized Medicine** The trend toward personalized or precision medicine is transforming the healthcare landscape in the United States, particularly in the field of cardiology. The incorporation of biomarker-driven strategies to tailor treatments to individual patient profiles enhances treatment efficacy and safety. The National Institutes of Health has noted that personalized medicine can lead to improvements in treatment outcomes and could potentially reduce healthcare costs by preventing ineffective treatments. This growth in demand for personalized medicine practices is driving the US Cardiac Biomarkers Market Industry as institutions such as Mayo Clinic and Cleveland Clinic continue to advocate for the adoption of biomarker tests. With an increase in clinical trials aimed at personalizing cardiovascular therapies, the momentum for biomarker development is expected to intensify, creating further market opportunities. ### **Government Initiatives and Funding for Cardiovascular Research** In the United States, government initiatives aimed at combating cardiovascular diseases are spurring growth in the cardiac biomarkers sector. Through programs such as the National Heart, Lung, and Blood Institute (NHLBI), significant funding has been allocated for research dedicated to innovative biomarker development and the enhancement of cardiovascular disease prevention strategies. A report indicated that federal funding for cardiovascular research approaches nearly 500 million USD annually, reflecting the growing recognition of heart diseases as a public health concern. Such financial backing encourages collaborations between universities, research institutions, and private firms in the US Cardiac Biomarkers Market Industry, driving innovation and development of new biomarker solutions. By promoting such partnerships, the government plays a critical role in shaping a robust pipeline for future growth in the market. ## **US Cardiac Biomarkers Market Segment Insights** ### **Cardiac Biomarkers Market Type Insights** The US Cardiac Biomarkers Market is steadily evolving, with a strong focus on the Type segmentation, which includes key components such as Creatine Kinase (CK-MB), Troponins T, Myoglobin, BNPs, Ischemia-modified albumin (IMA), and others. In the context of cardiac events, biomarkers play an indispensable role in diagnostics and patient monitoring, particularly in acute coronary syndrome. Troponins T have emerged as a major player in the Type segment due to their high sensitivity and specificity in diagnosing myocardial infarction, making them a gold standard for clinicians across the United States. Meanwhile, Creatine Kinase (CK-MB) continues to be utilized as a traditional marker, particularly for the early assessment of heart injury. The Biomarkers such as Myoglobin are gaining traction; they are known for their rapid release into the bloodstream following cardiac damage, enabling timely intervention. BNPs are crucial for evaluating heart failure, offering a vital diagnostic tool in emergency care settings. Meanwhile, Ischemia-modified albumin (IMA) has garnered interest for its potential to improve diagnosis in ischemic conditions. Each of these components addresses specific clinical needs and directly contributes to increasing diagnostic precision in the US Cardiac Biomarkers Market. With the rising prevalence of cardiovascular diseases and increased healthcare expenditure in the US, there's an intensified focus on advanced diagnostics, which opens up substantial opportunities for innovation in cardiac biomarkers. The Types segment will likely experience continued growth driven by advancements in laboratory technology and rising consumer awareness regarding heart health. This segment's diversity aids healthcare providers in making informed decisions, ultimately enhancing patient outcomes through personalized medicine approaches tailored to individual profiles, thereby significantly impacting overall health management strategies in cardiovascular care across the nation. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ### **Cardiac Biomarkers Market Location of Testing Insights** The Location of Testing segment within the US Cardiac Biomarkers Market plays a crucial role in the effective diagnosis and management of cardiac diseases. As healthcare continues to evolve, both Point of Care and Laboratory Testing are becoming increasingly significant in delivering timely results. Point of Care testing is favored for its rapid turnaround time, enabling healthcare providers to make swift clinical decisions, especially in emergency settings. This location of testing meets the growing demand for immediate diagnostics, which is essential considering the rising incidence of cardiovascular diseases across the United States. On the other hand, Laboratory Testing remains a cornerstone due to its comprehensive analytical capabilities and the ability to perform a wider array of tests, making it more suitable for complex cases that require detailed biomarkers analysis. Furthermore, advancements in technology and the increased adoption of telehealth services amplify the effectiveness of these testing locations. The trend toward decentralization in healthcare emphasizes the importance of both testing types as they contribute to improved patient outcomes and are likely to remain key drivers in the overall US Cardiac Biomarkers Market growth. ### **Cardiac Biomarkers Market Application Insights** The US Cardiac Biomarkers Market has shown notable potential in the Application segment, serving critical roles in diagnosing and managing various cardiovascular diseases. Myocardial Infarction represents a significant area within this segment, as timely identification can drastically enhance patient outcomes. Similarly, Congestive Heart Failure is becoming increasingly prevalent, necessitating advanced biomarkers for effective monitoring and treatment strategies. Acute Coronary Syndrome is another vital application, with biomarkers playing a crucial role in risk assessment and guiding therapeutic decisions. Atherosclerosis, characterized by arterial plaque buildup, relies on biomarkers for early detection and management, underscoring their importance in preventing severe cardiovascular events. The integration of advanced technologies in biomarker development is a growing trend, further driving market growth. As healthcare demands shift towards personalized medicine, the significance of accurate diagnostics and targeted therapies only intensifies, indicating strong future opportunities within these applications in the US Cardiac Biomarkers Market. The market growth is fueled by an increasing incidence of heart diseases and a rising focus on preventive healthcare measures among both consumers and healthcare providers. ## **US Cardiac Biomarkers Market Key Players and Competitive Insights** The US Cardiac Biomarkers Market is characterized by rapid growth and intense competition, emerging as a vital segment within the broader healthcare landscape. This market is primarily driven by the increasing prevalence of cardiovascular diseases, a growing aging population, and advancements in diagnostic technology. Key aspects that shape the competitive landscape include innovation in product development, collaboration with healthcare providers, and the establishment of extensive distribution networks. Companies compete on the ability to offer reliable, accurate, and timely diagnostic solutions that help in better patient management and care. The market dynamics also involve regulatory considerations and the need for manufacturers to comply with stringent quality standards, which further influences competitive strategies. ### **Key Player Analysis - Danaher Corporation** Danaher Corporation holds a prominent position in the US Cardiac Biomarkers Market, leveraging its strong reputation for innovation and quality. The company focuses on developing and providing comprehensive diagnostic solutions that cater to the needs of healthcare providers and laboratories across the country. Its strengths are highlighted by a robust portfolio of advanced technologies in molecular and immunoassay diagnostics that facilitate the accurate measurement of cardiac biomarkers. Danaher Corporation benefits from its strong distribution channels, which ensure accessibility to its products, as well as its commitment to research and development, allowing it to stay at the forefront of emerging trends in cardiac diagnostics. Their exceptional customer support and strategic partnerships with healthcare institutions further bolster their market presence in the US. ### **Key Player Analysis - Quidel Corporation** Quidel Corporation is another key player within the US Cardiac Biomarkers Market, offering a range of innovative products and services designed to enhance cardiac care. The company is recognized for its focus on rapid diagnostic testing solutions, which enable healthcare professionals to quickly identify cardiac conditions. Key offerings include point-of-care tests and laboratory diagnostics that streamlines the process of measuring biomarkers associated with cardiovascular disease. Quidel Corporation has established a solid market presence in the US, benefiting from its strong research capabilities and well-established brand reputation. Strategic mergers and acquisitions have also played a significant role in expanding their product offerings and capabilities, further enhancing their competitive positioning. The company continues to invest in technological advancements and maintain robust relationships with healthcare partners to drive growth in the US market. ### **Key Companies in the US Cardiac Biomarkers Market Include** ## **US Cardiac Biomarkers Market Industry Developments** The US Cardiac Biomarkers Market is experiencing notable developments, particularly in the context of high demand for accurate and rapid diagnostic tools amid rising cardiovascular diseases. Companies such as Danaher Corporation and Abbott Laboratories are actively expanding their product portfolios, investing in new technologies to enhance diagnostic capabilities. In July 2023, Roche Diagnostics announced a strategic partnership with a prominent company to bolster their research initiatives in cardiac markers, reflecting a trend towards collaboration for improved diagnostic efficiency. Additionally, Quidel Corporation saw significant growth in its market valuation, attributed to increasing sales of its innovative testing solutions. Moreover, in August 2023, Thermo Fisher Scientific completed its acquisition of a diagnostic asset that is anticipated to broaden its cardiac biomarker offerings, reinforcing its position in the market. Major industry players are continuously innovating, with HemoSonics launching a new point-of-care testing device in early 2023 aimed at providing rapid results for clinicians. These developments denote a thriving market environment, vital in addressing the escalating prevalence of heart-related ailments across the United States. ## **US Cardiac Biomarkers Market Segmentation Insights** ### **Cardiac Biomarkers Market Type Outlook** ### **Cardiac Biomarkers Market Location of Testing Outlook** ### **Cardiac Biomarkers Market Application Outlook** - Myocardial Infarction - Congestive Heart Failure - Acute Coronary Syndrome - Atherosclerosis ## Market Drivers ### Rising Awareness of Heart Health Public awareness campaigns focusing on heart health are contributing to the growth of the cardiac biomarkers market. As individuals become more informed about the risks associated with cardiovascular diseases, there is a heightened demand for preventive screening and diagnostic testing. Educational initiatives by health organizations are encouraging people to seek regular check-ups and screenings, which in turn drives the need for cardiac biomarkers. The cardiac biomarkers market is likely to see increased utilization of these tests as patients proactively manage their heart health. This trend not only supports early detection but also promotes a culture of preventive healthcare, ultimately leading to improved health outcomes and reduced healthcare costs. ### Advancements in Biomarker Research Ongoing research and development in the field of cardiac biomarkers are propelling the market forward. Innovations in biomarker discovery, including the identification of novel proteins and genetic markers, are enhancing diagnostic accuracy and expanding the range of available tests. The cardiac biomarkers market benefits from these advancements, as they lead to the development of more sensitive and specific assays. For instance, the introduction of high-sensitivity troponin tests has revolutionized the diagnosis of myocardial infarction, allowing for earlier detection and intervention. As research continues to unveil new biomarkers, the market is expected to experience substantial growth, with an increasing number of diagnostic products entering the market, thereby improving patient care and outcomes. ### Growing Demand for Point-of-Care Testing The shift towards point-of-care testing (POCT) is significantly influencing the cardiac biomarkers market. Healthcare providers are increasingly adopting POCT due to its ability to deliver rapid results, which is crucial in emergency settings. This trend is particularly relevant in the context of cardiac care, where timely diagnosis can be life-saving. The cardiac biomarkers market is witnessing a surge in the development of portable and user-friendly testing devices that can be utilized in various settings, including hospitals, clinics, and even at home. The convenience and efficiency of POCT are likely to drive market growth, as patients and providers alike seek solutions that enhance the speed and accessibility of cardiac diagnostics. ### Rising Incidence of Cardiovascular Diseases The increasing prevalence of cardiovascular diseases in the US is a primary driver for the cardiac biomarkers market. According to the American Heart Association, cardiovascular diseases account for approximately 697,000 deaths annually, representing about 1 in every 5 deaths. This alarming statistic underscores the urgent need for effective diagnostic tools, including cardiac biomarkers, to facilitate early detection and management of heart conditions. As healthcare providers seek to improve patient outcomes, the demand for innovative biomarker tests is likely to rise. The cardiac biomarkers market is thus positioned for growth, as these tests enable clinicians to assess risk, guide treatment decisions, and monitor disease progression, ultimately contributing to better healthcare delivery and patient management. ### Increased Investment in Healthcare Infrastructure Investment in healthcare infrastructure in the US is a significant driver for the cardiac biomarkers market. As hospitals and clinics expand their capabilities, there is a growing emphasis on integrating advanced diagnostic technologies, including cardiac biomarkers. This trend is supported by government initiatives aimed at improving healthcare access and quality. The cardiac biomarkers market stands to benefit from these investments, as healthcare facilities upgrade their laboratories and diagnostic equipment to accommodate new biomarker tests. Furthermore, increased funding for research and development in the healthcare sector is likely to foster innovation, leading to the introduction of new and improved cardiac biomarker assays that enhance patient care. ## Future Outlook The [Cardiac Biomarkers Market](https://www.marketresearchfuture.com/reports/cardiac-biomarkers-market-8594) is projected to grow at a 12.02% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of cardiovascular diseases, and rising demand for point-of-care testing. **New opportunities:** - Development of portable diagnostic devices for remote patient monitoring. - - Integration of AI-driven analytics for personalized treatment plans. - Expansion of telehealth services to enhance patient access to biomarker testing. By 2035, the cardiac biomarkers market is expected to achieve substantial growth, driven by innovation and increased healthcare accessibility. ## Segment Insights ### By Type: Troponins T and I (Largest) vs. Creatine Kinase (CK-MB) (Fastest-Growing) In the US cardiac biomarkers market, the Troponins T and I segment holds the largest market share, reflecting its critical role in diagnosing acute myocardial infarction. This dominance is predominantly due to the high specificity and sensitivity of troponins in heart injury detection, making them the preferred choice for clinicians. Comparatively, Creatine Kinase (CK-MB) holds a notable position but trails behind troponins in terms of market share, having traditionally been a standard marker for cardiac damage. The growth trends within the type segment indicate that while Troponins T and I will continue to be preferred, Creatine Kinase (CK-MB) is experiencing heightened interest as a complementary biomarker, especially in specific patient populations. Factors driving this growth include advancements in testing technologies and an increasing number of heart-related diseases, pushing healthcare providers to adopt comprehensive diagnostic approaches that include both troponins and CK-MB. Troponins T and I (Dominant) vs. Creatine Kinase (CK-MB) (Emerging) Troponins T and I represent the dominant segment within the US cardiac biomarkers market due to their unmatched accuracy in diagnosing cardiac events. Their ability to detect heart muscle injury very quickly makes them a gold standard in this field. On the other hand, Creatine Kinase (CK-MB) is emerging as a significant complement to troponins, particularly in cases where timing and diagnosis complexity require a broader spectrum of biomarkers. While CK-MB has been in use for decades, its resurgence is fueled by advancements in assay technologies and a growing recognition of its utility in specific clinical scenarios, enhancing its market relevance. ### By Location of Testing: Point of Care (Largest) vs. Laboratory Testing (Fastest-Growing) In the US cardiac biomarkers market, the distribution of testing locations highlights the dominance of the Point of Care segment, which captures the largest market share due to increasing demand for rapid and accessible testing solutions. This preference is largely driven by the need for immediate results in emergency situations and routine monitoring, making Point of Care a crucial player in the market. On the other hand, Laboratory Testing is emerging as the fastest-growing segment, benefiting from advancements in technology that improve accuracy and expand the range of biomarkers that can be tested. The evolving healthcare landscape, which emphasizes comprehensive diagnostics and personalized treatment strategies, further fuels the growth of Laboratory Testing, as healthcare providers increasingly rely on lab results for informed decision-making. Testing Location: Point of Care (Dominant) vs. Laboratory Testing (Emerging) Point of Care testing is characterized by its ability to deliver immediate results at the patient's location, making it vital in urgent care settings. This convenience has made it the dominant method for cardiac biomarker analysis, particularly in scenarios requiring quick clinical decisions. Conversely, Laboratory Testing, though slower, is highly regarded for its thoroughness and precision, positioning it as the emerging choice among healthcare providers seeking comprehensive data for complex cases. Together, these two segments reflect the diverse needs and preferences within the US cardiac biomarkers market, illustrating a trend towards more rapid yet accurate diagnostic solutions. ### By Application: Myocardial Infarction (Largest) vs. Congestive Heart Failure (Fastest-Growing) In the US cardiac biomarkers market, the application segment is predominantly led by Myocardial Infarction, showcasing the largest market share due to its critical role in diagnosing heart conditions. Congestive Heart Failure follows closely as both a significant concern and a focus of innovation, reflecting a substantial portion of the market as healthcare providers emphasize its importance in cardiac diagnostics. Growth trends within this segment reveal a notable rise in the use of biomarkers for early diagnosis and monitoring of heart diseases. Factors driving this expansion include advancements in testing technologies and increasing awareness of cardiovascular conditions. The growing prevalence of risk factors such as obesity and diabetes fuels demand for reliable cardiac biomarkers, thereby accelerating market growth. Myocardial Infarction (Dominant) vs. Atherosclerosis (Emerging) Myocardial Infarction remains the dominant application within the US cardiac biomarkers market, characterized by its critical significance in emergency care and ongoing advancements in biomarker development. This segment benefits from established diagnostic protocols and strong clinical acceptance, leading to significant investments in research and innovation. Conversely, Atherosclerosis is recognized as an emerging segment, gaining traction due to increasing awareness of its role in cardiovascular diseases. This application is seeing enhanced research focus, supported by the need for comprehensive screening programs to identify and manage cardiovascular risks earlier. As both segments evolve, their contributions to improving patient outcomes continue to reshape the landscape of cardiac diagnostics. ## Competitive Benchmarking The [cardiac biomarkers market](https://www.marketresearchfuture.com/reports/cardiac-biomarkers-market-8594) is characterized by a dynamic competitive landscape, driven by advancements in diagnostic technologies and an increasing prevalence of cardiovascular diseases. Key players such as Roche Diagnostics (CH), Abbott Laboratories (US), and Siemens Healthineers (DE) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Roche Diagnostics (CH) focuses on expanding its product portfolio through continuous research and development, while Abbott Laboratories (US) emphasizes digital health solutions to improve patient outcomes. Siemens Healthineers (DE) is investing in AI-driven diagnostics, which appears to be a significant trend shaping the competitive environment.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure is moderately fragmented, with several players competing for market share. The collective influence of these key players fosters a competitive atmosphere where innovation and operational excellence are paramount. In October Abbott Laboratories (US) announced a strategic partnership with a leading telehealth provider to integrate cardiac biomarker testing into remote patient monitoring systems. This move is likely to enhance patient access to critical diagnostics, aligning with the growing trend of telemedicine and remote healthcare solutions. By integrating their testing capabilities with telehealth, Abbott Laboratories (US) positions itself as a leader in the evolving landscape of digital health. In September Roche Diagnostics (CH) launched a new cardiac biomarker assay that utilizes advanced nanotechnology to improve sensitivity and specificity. This innovation is expected to significantly enhance diagnostic accuracy, thereby potentially increasing the company's market share. The introduction of this assay reflects Roche's commitment to maintaining its competitive edge through cutting-edge technology and innovation. In August Siemens Healthineers (DE) expanded its portfolio by acquiring a startup specializing in AI-driven diagnostic tools for cardiac diseases. This acquisition is indicative of Siemens' strategy to integrate artificial intelligence into its product offerings, which may lead to more efficient and accurate diagnostics. The move not only strengthens Siemens' market position but also highlights the increasing importance of AI in the cardiac biomarkers market. As of November current trends in the cardiac biomarkers market include a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming increasingly vital, as companies seek to enhance their capabilities and market reach. The competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize these aspects will be better positioned to thrive in the future. ## Recent News & Developments The US Cardiac Biomarkers Market is experiencing notable developments, particularly in the context of high demand for accurate and rapid diagnostic tools amid rising cardiovascular diseases. Companies such as Danaher Corporation and Abbott Laboratories are actively expanding their product portfolios, investing in new technologies to enhance diagnostic capabilities. In July 2023, Roche Diagnostics announced a strategic partnership with a prominent company to bolster their research initiatives in cardiac markers, reflecting a trend towards collaboration for improved diagnostic efficiency. Additionally, Quidel Corporation saw significant growth in its market valuation, attributed to increasing sales of its innovative testing solutions. Moreover, in August 2023, Thermo Fisher Scientific completed its acquisition of a diagnostic asset that is anticipated to broaden its cardiac biomarker offerings, reinforcing its position in the market. Major industry players are continuously innovating, with HemoSonics launching a new point-of-care testing device in early 2023 aimed at providing rapid results for clinicians. These developments denote a thriving market environment, vital in addressing the escalating prevalence of heart-related ailments across the United States. ## Report Scope | MARKET SIZE 2024 | 3072.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 3441.25(USD Million) | | MARKET SIZE 2035 | 10709.28(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 12.02% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Roche Diagnostics (CH), Abbott Laboratories (US), Siemens Healthineers (DE), Ortho Clinical Diagnostics (US), Thermo Fisher Scientific (US), bioMérieux (FR), QuidelOrtho Corporation (US), Boehringer Ingelheim (DE), F. Hoffmann-La Roche AG (CH) | | Segments Covered | Type, Location of Testing, Application | | Key Market Opportunities | Advancements in point-of-care testing technologies enhance accessibility in the cardiac biomarkers market. | | Key Market Dynamics | Rising demand for rapid diagnostic tests drives innovation in cardiac biomarkers and enhances competitive market dynamics. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US cardiac biomarkers market in 2024?** A: The market valuation of the US cardiac biomarkers market was $3072.0 Million in 2024. **Q: What is the projected market valuation for the US cardiac biomarkers market by 2035?** A: The projected market valuation for the US cardiac biomarkers market is $10709.28 Million by 2035. **Q: What is the expected CAGR for the US cardiac biomarkers market during the forecast period 2025 - 2035?** A: The expected CAGR for the US cardiac biomarkers market during the forecast period 2025 - 2035 is 12.02%. **Q: Which company is a key player in the US cardiac biomarkers market?** A: Roche Diagnostics is one of the key players in the US cardiac biomarkers market. **Q: What are the main types of cardiac biomarkers and their market values?** A: Troponins T and I have a market value range of $1200.0 - $4000.0 Million, while Creatine Kinase (CK-MB) ranges from $300.0 - $1000.0 Million. **Q: What is the market value range for Point of Care testing in the US cardiac biomarkers market?** A: The market value range for Point of Care testing in the US cardiac biomarkers market is $1228.8 - $4260.0 Million. **Q: What applications are driving the US cardiac biomarkers market?** A: Congestive Heart Failure is projected to have a market value range of $900.0 - $3200.0 Million, indicating its significance in the US cardiac biomarkers market. **Q: How does the market value for Laboratory Testing compare to Point of Care testing?** A: The market value for Laboratory Testing ranges from $1843.2 - $6449.28 Million, which is higher than that of Point of Care testing. **Q: What is the market value range for Myocardial Infarction applications in the US cardiac biomarkers market?** A: The market value range for Myocardial Infarction applications is $800.0 - $2800.0 Million. **Q: Which companies are involved in the development of cardiac biomarkers?** A: Companies such as Abbott Laboratories, Siemens Healthineers, and Thermo Fisher Scientific are involved in the development of cardiac biomarkers. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-cardiac-biomarkers-market-12821*